These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 23956204

  • 1. Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
    Chao YH, Wu KH, Lin CY, Tsai MH, Peng CT, Wu HP, Lin CD.
    Pediatr Blood Cancer; 2013 Dec; 60(12):1963-6. PubMed ID: 23956204
    [Abstract] [Full Text] [Related]

  • 2. Audiologic and vestibular assessment in children and adolescents with transfusion dependent beta thalassemia major: The era of deferasirox film coated tablet.
    Galhom DH, Talaat RM, Hanna D, Gad NH.
    Int J Pediatr Otorhinolaryngol; 2024 Feb; 177():111868. PubMed ID: 38252990
    [Abstract] [Full Text] [Related]

  • 3. Long term audiological evaluation of beta-thalassemic patients.
    Kontzoglou G, Koussi A, Economou M, Tsatra I, Perifanis V, Noussios G, Athanassiou-Metaxa M.
    Acta Otorhinolaryngol Belg; 2004 Feb; 58(2):113-7. PubMed ID: 15515654
    [Abstract] [Full Text] [Related]

  • 4. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation.
    Osma U, Kurtoglu E, Eyigor H, Yilmaz MD, Aygener N.
    Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754
    [Abstract] [Full Text] [Related]

  • 5. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
    Chiodo AA, Alberti PW, Sher GD, Francombe WH, Tyler B.
    J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Effect of inner ear hearing loss on delayed otoacoustic emissions (TEOAE) and distortion products (DPOAE)].
    Hoth S.
    Laryngorhinootologie; 1996 Dec; 75(12):709-18. PubMed ID: 9081275
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment.
    Ambrosetti U, Dondè E, Piatti G, Cappellini MD.
    Pharmacol Res; 2000 Nov; 42(5):485-7. PubMed ID: 11023713
    [Abstract] [Full Text] [Related]

  • 13. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.
    Blood Cells Mol Dis; 2009 Nov; 42(3):247-51. PubMed ID: 19233692
    [Abstract] [Full Text] [Related]

  • 14. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF, Peng CT, Wu KH, Tsai CH.
    Hemoglobin; 2006 Nov; 30(2):215-8. PubMed ID: 16798646
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inner ear dysfunction in myotonic dystrophy type 1.
    Balatsouras DG, Felekis D, Panas M, Xenellis J, Koutsis G, Kladi A, Korres SG.
    Acta Neurol Scand; 2013 May; 127(5):337-43. PubMed ID: 23121018
    [Abstract] [Full Text] [Related]

  • 19. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 May; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 20. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Hemoglobin; 2011 May; 35(3):206-16. PubMed ID: 21599433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.